These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17167764)

  • 1. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
    Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ
    Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
    Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
    Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
    Dolezal J; Vizda J; Odrazka K
    Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
    Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E
    Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.
    Menda Y; Bushnell DL; Williams RD; Miller S; Thomas MO
    Clin Nucl Med; 2000 Sep; 25(9):698-700. PubMed ID: 10983757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Samarium-153-lexidronam therapy for metastatic bone pain.
    Ribera H
    J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):80-1; discussion 81-2. PubMed ID: 23527672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
    Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
    Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
    Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
    J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
    Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D
    Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
    Higano CS; Quick DP; Bushnell D; Sartor O
    Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Samarium-153 lexidronam for painful bone metastases.
    Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.
    Paravati AJ; Russo AL; Aitken C
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):506-10. PubMed ID: 20888141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
    Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
    J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
    Wang RF; Zhang CL; Zhu SL; Zhu M
    Med Princ Pract; 2003; 12(2):97-101. PubMed ID: 12634464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
    Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
    J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
    Correa-González L; Arteaga de Murphy C; Pichardo-Romero P; Pedraza-López M; Moreno-García C; Correa-Hernández L
    Arch Med Res; 2014 May; 45(4):301-8. PubMed ID: 24681187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005).
    Barnard SM; Zuber RM; Moore AS
    J Am Vet Med Assoc; 2007 Jun; 230(12):1877-81. PubMed ID: 17571994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
    Lin J; Sinibaldi VJ; Carducci MA; Denmeade S; Song D; Deweese T; Eisenberger MA
    Urol Oncol; 2011; 29(6):670-5. PubMed ID: 19962920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
    Skalli S; Desruet MD; Bourre JC; Caravel JP; Vuillez JP
    Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy.
    Heron DE; Brufsky A; Beriwal S; Kurman M
    Ann Oncol; 2008 Sep; 19(9):1639-43. PubMed ID: 18467311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.